LONSURF® is Available at Onco360
This limited distribution medication is only available from a select number of pharmacies nationwide.
LONSURF is a limited distribution oral cancer medication just approved by the F.D.A. for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.
|APPROVED INDICATION1||RECOMMENDED DOSAGE1|
LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Recommended dose: 35 mg/m2/dose orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Take LONSURF within 1 hour after completion of morning and evening meals.
According to the American Cancer Society, approximately 136,830 people will be diagnosed with mCRC in the United States annually, a subset of which will become candidates for treatment with LONSURF2.
- Cancer facts & figures 2014. American Cancer Society.
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.